/Content/Upload/Product/AngioFlammaFAM_diagnocine_1200.jpg

AngioFlamma® FAM

Product#: ARW1025

$939.52

Size of product (mg)

1 mg
5 mg

Qty:

Availability:

Ships in 1-2 Weeks

AngioFlamma® FAM

Cat. No. List below

Description

AngioFlamma® FAM is an advanced angiogenesis imaging fluorescent probe designed for in vivo visualization of blood vessels, tumors, and angiogenesis. This innovative probe consists of a cyclic RGD (Arg-Gly-Asp) peptide covalently linked to a FAM (fluorescein amidite) dye, creating a powerful tool for researchers and clinicians studying vascular development and tumor growth.

Key Features:
1. Cyclic RGD peptide with high affinity for αvβ3 integrin
2. FAM fluorophore with excitation/emission maxima at 492/519 nm
3. Molecular weight of 978.01 g/mol
4. Yellow solid appearance
5. Storage at -20°C, protected from light

Applications:
1. In vivo imaging of blood vessels
2. Tumor visualization and monitoring
3. Angiogenesis research
4. Evaluation of anti-angiogenic therapies
5. Study of integrin expression in various tissues

Advantages:
1. High specificity: The cyclic RGD peptide binds preferentially to αvβ3 integrin, which is highly expressed in many solid tumors and actively growing blood vessels.
2. Versatile binding: AngioFlamma® FAM can also interact with other integrins (αvβ5, α5β1, α6β4, α4β1, and αvβ6), potentially enhancing tumor uptake and providing a more comprehensive view of the angiogenic process.
3. Sensitive detection: The FAM fluorophore offers bright fluorescence in the green spectrum, allowing for sensitive imaging of target structures.
4. Non-invasive imaging: Enables real-time, non-invasive visualization of angiogenesis and tumor development in living subjects.
5. Compatibility: Suitable for use with common fluorescence imaging systems and microscopes equipped with FITC filter sets.
6. Quantitative analysis: Allows for quantitative assessment of angiogenesis and integrin expression in various tissues and tumors.
7. Translational potential: Provides valuable insights into angiogenesis that can be applied to drug development and therapeutic monitoring.

AngioFlamma® FAM serves as a powerful tool for researchers and clinicians studying vascular biology, cancer progression, and the efficacy of anti-angiogenic therapies. Its ability to selectively target areas of active angiogenesis makes it an invaluable asset in the field of molecular imaging and biomedical research.

Specifications

Fluorophore: FAM
Application: Angiogenesis imaging
Excitation/Emission Max.(nm): 492/519 nm
Molecular weight: 978.01 g/mol
Appearance: Yellow Solid
Storage conditions: -20 ℃, protect from light

Table 1. List of Annexin V-Flamma® apoptosis detection kits

Quick link (Cat.#)	Series	λEx (nm)	λEm (nm)	Common filter set	Excitation source	Size
ARW1025	AngioFlamma® FAM	492	519	FITC	488 nm	0.5mg, 1mg, 5mg
ARW1011	AngioFlamma® 552	550	565	TRITC	488, 532 nm	0.5mg, 1mg, 5mg
ARR1001	AngioFlamma® TAMRA	543	575	TRITC	488, 532 nm	0.5mg, 1mg, 5mg
ARW1415	AngioFlamma® 581	581	596	TRITC	488, 532 nm	0.5mg, 1mg, 5mg
ARW1215	AngioFlamma® 648	648	663	Cy®5	594, 633 nm	0.5mg, 1mg, 5mg
ARW1501	AngioFlamma® 675	675	691	Cy®5.5	633, 680 nm	0.5mg, 1mg, 5mg
ARW1301	AngioFlamma® 749	749	774	Cy®7	680 nm	0.5mg, 1mg, 5mg
ARW1601	AngioFlamma® 774	774	806	Cy®7.5	785 nm	0.5mg, 1mg, 5mg
ARO1601	AngioFlamma® ICG	785	821	Cy®7.5	785 nm	0.5mg, 1mg, 5mg

Background

Integrins are heterodimeric transmembrane receptors for cell adhesion to extracellular matrix (ECM) proteins and play important roles in certain cell-cell adhesions. In addition, they make transmembrane connections to the cytoskeleton and activate many intracellular signaling pathways. Because of their role in tumor angiogenesis and progression, integrins have become important diagnostic and therapeutic targets. Integrin αvβ3 is generally expressed in low levels on the epithelial cells and mature endothelial cells, but it is highly expressed in many solid tumors. The αvβ3 levels correlate well with the potential for tumor metastasis and aggressiveness, which make it an important biological target for development of antiangiogenic drugs and molecular imaging probes for early tumor diagnosis. Cyclic tripeptide arginine-glycine-aspartate (RGD) is wellknown to bind preferentially to αvβ3 integrin with high affinity. Cyclic RGD is an effective ligand for tumor targeting since integrin αvβ3 is overexpressed not only on tumoral endothelium but also on various cancer cells. Thus, targeting tumor cells or tumor vasculature by RGD-based strategies is a promising approach for delivering anticancer drugs or diagnostic agents. Cyclic RGD peptides are also able to bind αvβ5, α5β1, α6β4, α4β1, and αvβ6 integrins, which may help enhance their tumor uptake due to the increased receptor population. BioActs developed AngioFlamma® series as effective fluorescent probes for the detection of angiogenesis and tumor cells. The probes are made up of various fluorophores conjugated cyclic RGD. We offer AngioFlamma® series as in vivo fluorescent probes for imaging of blood vessels, tumors and angiogenesis.

Figure 1. Breast cancer cell imaging using AngioFlamma® 675

In vivo Imaging protocol

1. Preparation of Xenograft tumor model

① MDA-MB-231 human breast cancer cells (1.0 x 10⁷) are injected subcutaneously on the female nude mouse shoulder.
② After the tumor cells have grown to about 50-80 mm³, administer the drug.

2. Injection and Fluorescence imaging

① Fluorescence imaging would be performed up to 24 hours after injection using the optical imaging system.
② Prepared mice is injected intravenously with 100 μg / 200 μL of AngioFlamma® series and images will be taken at appropriate time interval.

Citation & Reference

Yumin Zheng. FITC-Conjugated Cyclic RGD Peptides as Fluorescent Probes for Staining Integrin αvβ3/αvβ5 in Tumor Tissues. Bioconjug Chem 25.1 (2014): 1925-41.
Dongfang Yue. Biomarker-targeted fluorescent probes for breast cancer imaging. Chinese Chemical Letters 29.5 (2018): 648-656.